Home
overview

What is this event about?

Pain

SMi ran its first conference on pain therapeutics in 2001, and has run a highly successful conference on this topic every year since.  In 2010, our industry-leading Pain Therapeutics conference returns for its tenth year, and will build on the knowledge-base and reputation that SMi has in this area to deliver the most interesting and informative conference yet.

Taking place in London, UK, this conference will look at a wide range of issues withing the pain therapeutics arena.  It will combine a study of the latest successes in the research and development phase with presentations covering the key themes of biomarkers and the cannabinoid approach.

Questions examined during the conference will include: Do cannabinoid medicines have a place in our pain arsenal?  How do regulatory authorities treat emerging clinical development biomarkers.  What are the latest targets being researched?  How do we treat associated conditions for chronic pain?    How effective is translational research for pain measurement?  Attend this event to discover the latest success stories in researching and marketing pain therapeutics. 

 

Fancy speaking at the conference?  Do you know of anyone who may be interested in speaking?  We are always on the look-out for new speakers for our upcoming conferences.  Let us know: smiproduction@smi-online.co.uk.

For sponsorship and exhibitioning opportunities, contact sponsorshipdept@smi-online.co.uk 

 Why should you attend this event?

Delegates at this conference will learn about

  • The latest successes and failures for new targets and drugs
  • The use and regulation of biomarkers for early drug development
  • The cannabinoid approach to pain therapeutics
  • Animal models and translational approaches
  • Options and pitfalls in early drug development
  • Biologics for the treatment of pain
 Pain 2
 Pain medication

How you will benefit from attending this conference

Hear from some of the most important and influential experts working in pain therapeutics

Learn about the challenges of early drug development

Study the latest targets and compounds being researched

Network with people you need to know in the pain therapeutics world

Who is speaking at this event?

Our keynote speakers

Chas Bountra
Chief Scientist, Structural Genomics Consortium
University of Oxford

José Miguel Vela
Basic Research & Drug Discovery
Esteve

Sharon Bingham
In Vivo Pharmacology & Translational Science
GlaxoSmithKline

Steve England
Associate Research Fellow
Pfizer

Lars Arendt-Nielsen
Director, Centre for Sensory-Motor Interaction
Aalborg University

Our expert speakers

Odd-Geir Berge, Senior Principal Scientist, AstraZeneca

Arthur Gomtsyan, Associate Research Fellow, Neuroscience and Pain Research, Abbott Laboratories

Martin Koltzenburg, Chair of Clinical Neurophysiology and Deputy Director, Centre for Neuromuscular Disease

Adrian Mogg, Research Scientist - Pain-Migraine DHT, Eli Lilly

Aldemar Degroot, Associate Scientific Director, Exploratory Development Department, Astellas

David Finn, Co-Director, Centre for Pain Research, Pharmacology & Therapeutics, National University of Ireland, Galway

Tim Young, Associate Research Fellow, Pfizer

Jeffrey Tobias, Chief Medical Officer, NeurogesX

Wia Timmerman, Project Leader, Pain/fMRI Research Initiative, TI Pharma Consortium

Isabel Gonzalez, Head of Biology, Proximagen Neuroscience

Karen Maubach, Group Manager of Project Management, BTG

Who should attend this event?

Chief Executives, Vice Presidents, Heads, Directors, Chief Scientists and Project Leaders of

  • Pain Discovery
  • Exploratory Development
  • Pain Research
  • Neurosciences
  • Translational Research
  • CNS Therapeutic area
  • Discovery Chemistry
  • Molecular Medicine
  • Molecular Discovery Research
  • Molecular Biology and Chemistry
  • Regulatory Affairs
  • Business Development

 Delegates at our 2009 Pain Therapeutics conference came from across the world

Graph of delegate countries

 Where is the event being held? 

Crowne Plaza London - The City

The Crowne Plaza London - The City is a modern and stylish central London hotel in the heart of the City of London.  This deluxe hotel is just a step from Blackfriars Mainline Train Station which has a direct connection to St. Pancras International Eurostar Terminal.

The hotel is a short walk from either Temple or Mansion House tube stations on the District & Circle lines or from St Paul's tube station on the Central Line.  Blackfriars tube station is currently closed due to the extensive renovation works taking place as part of the new Crossrail project.

Crowne Plaza London - The City is ideally located for business and leisure, minutes away from some of London's most famous attractions: The London Eye, St Paul's Cathedral, the Millennium Bridge, Tate Modern and West End theatres.

Crowne Plaza Club rooms, King Studios and Suites are available at your request. High Speed Internet access is offered in all fully air-conditioned bedrooms.

Indulge at one of the hotel's three restaurants or bar.  Our acclaimed award winning Refettorio restaurant, directed by Michelin starred Chef Giorgio Locatelli, is the place to be seen in the city.  A sensational asian alternative is the newly opened Chinese Cricket Club.  For those seeking fitness and relaxation, our Fitness Club with sauna is complimentary to all hotel guests. 

Crowne Plaza London - The City

  

19 New Bridge Street  EC4V 6DB

Tel: +44 (0) 870 4009 190    Fax: +44 (0) 207 4388 080

Book your accommodation at SMi discounted rates by calling us on +44 (0)870 9090 713, sending a fax to +44 (0)870 9090 714 or emailing hotels@smi-online.co.uk.

Conference programme

8:30 Registration and coffee

9:00 Chairman's opening remarks

Chas Bountra

Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford

9:10 Regulatory challenges for new neuropathic pain therapeutics

Jeffrey Tobias

Jeffrey Tobias, Chief Medical Officer, NeurogesX

  • Regulatory issues related to neuropathic pain product approvals
  • Differences between the USA and the EU regulatory perspectives
  • Innovative solutions utilised for recent approvals of Qutenza® in the EU and USA
  • 9:50 The use of quantitative human pain biomarkers in early drug development

    Lars Arendt-Nielsen

    Lars Arendt-Nielsen, Director, Centre for Sensory-Motor Interaction, Aalborg University

  • Advanced mechanism-based human pain biomarkers
  • Human proof-of-concept studies in analgesic drug development
  • Pain mechanism based target validation
  • 10:30 Morning coffee

    11:00 Translational neurophysiological biomarkers of peripheral nerve function

    Martin Koltzenburg

    Martin Koltzenburg, Chair of Clinical Neurophysiology and Deputy Director, Centre for Neuromuscular Disease

  • Ion channels in peripheral nerves as a target for novel analgesic drugs and prevention of neuropathies
  • Nerve excitability testing provides a novel translational tool to examine non-invasively  the function of different ion channel classes, including voltage-gated sodium channels and potassium channels
  • Drugs affect these excitability parameters differentially and allow direct assessment of target engagement
  • 11:40 Discovery of TRPV1 antagonists for pain management: Issues and opportunities

    Arthur  Gomtsyan

    Arthur Gomtsyan, Associate Research Fellow, Neuroscience and Pain Research, Abbott Laboratories

  • Discovery of Abbott TRPV1 antagonist clinical candidate 
  • Chemistry and preclinical pharmacology 
  • Temperature effects of TRPV3 antagonists
  • 12:20 Networking lunch

    13:50 Predictive validity of animal models for analgesia - what's ahead?

    Odd-Geir Berge

    Odd-Geir Berge, Senior Principal Scientist, AstraZeneca

  • Where are we with current models?
  • Future choices - Black-box or mechanistic modelling?
  • Emerging approaches
  • 14:30 Pain modulation and transmission at cannabinoid receptors

    Aldemar Degroot

    Aldemar Degroot, Associate Scientific Director, Exploratory Development Department, Astellas

  • The cannabinoid receptors and pain
  • Agonists
  • Endocannabinoids
  • Recent developments
  • Future prospects
  • 15:10 Afternoon tea

    15:40 Does chromatin or epigenetic modification offer an alternative approach to the treatment of chronic, clinical pain states?

    Chas Bountra

    Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford

  • What is epigenetics?
  • Role of environment and stress
  • Evidence in pain and inflammation
  • Potential pitfalls
  • 16:20 Regulation of endogenous analgesia by the endocannabinoid system: sites and mechanisms of action

    David Finn

    David Finn, Co-Director, Centre for Pain Research, National University of Ireland, Galway

  • Role of the endocannabinoid system in stress-induced analgesia
  • Activity in supraspinal components of the descending inhibitory pain pathway
  • Neurochemical and molecular mechanisms
  • 17:00 Chairman's closing remarks and close of day one

    8:30 Re-registration and coffee

    9:00 Chairman's opening remarks

    Tim Young

    Tim Young, Associate Research Fellow, Pfizer

    9:10 Targeting the endocannabinoid system for pain

    Tim Young

    Tim Young, Associate Research Fellow, Pfizer

  • The challenges of agonist development
  • Modulation of endocannabinoid tone
  • Future perspectives
  • 9:50 Options and pitfalls in early drug development

    Wia Timmerman

    Wia Timmerman, Project Leader, Pain/fMRI Research Initiative, TI Pharma

  • Experimental pain models in healthy volunteers
  • Phenotyping of patients with chronic pain using quantitative sensory testing 
  • Healthy volunteer models and patient studies: potential for fMRI
  • 10:30 Morning coffee

    11:00 Challenges in preclinical pain research

    Isabel Gonzalez

    Isabel Gonzalez, Head of Biology, Proximagen Neuroscience

  • Why work on pain research
  • Current animal models
  • The way forward
  • 11:40 Preclinical ion channel targets for next generation analgesics

    Steve England

    Steve England, Associate Research Fellow, Pfizer

  • Progress with isoform-selective voltage-gated sodium channel modulators
  • The ups and downs of TRP channels
  • Emerging targets
  • 12:20 Networking lunch

    13:50 Advances in the development of TRPA1 ligands - pharmacology and future directions

    Adrian Mogg

    Adrian Mogg, Research Scientist - Pain-Migraine DHT, Eli Lilly

  • Introduction to the TRP super-family
  • Preclinical rationale for TRPA1
  • Pharmacology and insights
  • Efficacy in vivo
  • Future directions
  • 14:30 The use of Laser Doppler Flowmetry (LDF) to measure cutaneous blood flow in rats: a potential translational biomarker for clinical pain studies

    Sharon Bingham

    Sharon Bingham, In Vivo Pharmacology & Translational Science, GlaxoSmithKline

  • What measurement of cutaneous blood flow can tell us about pain mechanisms: target engagement vs. surrogate end points 
  • Optimisation and validation of a preclinical model of electrically evoked changes in blood flow using Laser Doppler Flowmetry 
  • Advantages of this technique from an ethical perspective: the 3Rs
  • 15:10 Afternoon tea

    15:40 Prostanoid EP4 receptor antagonists as novel pain therapeutics

    Karen Maubach

    Karen Maubach, Group Manager of Project Management, BTG

  • Pivotal role of EP4 receptor in both pain and inflammation
  • Latest evidence from pre-clinical and experimental medicine models
  • EP4 receptor antagonists offer potential to be effective and better tolerated analgesics
  • 16:20 Pharmacological characterisation of a new sigma-1 receptor antagonist for the treatment of neuropathic pain

    José Miguel Vela

    José Miguel Vela, Basic Research & Drug Discovery, Esteve

  • Sigma-1 receptors play a key role in modulating activity-induced sensitisation in nociceptive pathways and are thus a new potential target of action for drugs designed to alleviate neuropathic pain
  • A new and selective sigma-1 receptor antagonist (S1RA) has been developed by Esteve that inhibits neuropathic pain behaviours in rodents
  • Safety and efficacy data support S1RA as a new therapeutic agent for the treatment of neuropathic pain
  • Human clinical trials are ongoing
  • 17:00 Chairman's closing remarks and close of conference

    +

    Workshops

    Translation from Model to Man and Back
    Workshop

    Translation from Model to Man and Back

    Crowne Plaza - The City
    9th June 2010
    London, United Kingdom

    Crowne Plaza - The City

    19 New Bridge Road
    London EC4V 6DB
    United Kingdom

    Crowne Plaza - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.